These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35076344)

  • 61. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.
    Zhu L; Wu G; Heng W; Zang X
    Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2053-2057. PubMed ID: 34862873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
    Lerond J; Lothe A; Ryvlin P; Bouvard S; d'Amato T; Ciumas C; Daléry J; Poulet E; Saoud M
    J Clin Psychopharmacol; 2013 Feb; 33(1):84-9. PubMed ID: 23277246
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Delusional infestation with unusual pathogens: a report of three cases.
    Dewan P; Miller J; Musters C; Taylor RE; Bewley AP
    Clin Exp Dermatol; 2011 Oct; 36(7):745-8. PubMed ID: 21933231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Successful treatment of delusional disorder of the somatic type or "delusional parasitosis" with olanzapine.
    Bosmans A; Verbanck P
    Pharmacopsychiatry; 2008 May; 41(3):121-2. PubMed ID: 18484558
    [No Abstract]   [Full Text] [Related]  

  • 67. Delusional parasitosis: lessons learnt.
    Ahmad K; Ramsay B
    Acta Derm Venereol; 2009; 89(2):165-8. PubMed ID: 19326002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Psychosis, ivermectin toxicity, and "Morgellons disease".
    DeBonis K; Pierre JM
    Psychosomatics; 2011; 52(3):295-6. PubMed ID: 21565604
    [No Abstract]   [Full Text] [Related]  

  • 69. Morgellons disease: a narrative review.
    Dib El Jalbout J; Sati H; Ghalloub P; El Bejjani G; Karam R; Mago A; Salame M; Saoudi L; Desangles AB; Emmanuel N
    Neurol Sci; 2024 Jun; 45(6):2579-2591. PubMed ID: 38319480
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Morgellons Disease Presenting As an Eyelid Lesion.
    Sandhu RK; Steele EA
    Ophthalmic Plast Reconstr Surg; 2016; 32(4):e85-7. PubMed ID: 25192328
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome.
    Gulisano M; Calì PV; Cavanna AE; Eddy C; Rickards H; Rizzo R
    Neurol Sci; 2011 Dec; 32(6):1213-7. PubMed ID: 21732066
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: Implication of inhibition of vesicular transport.
    Matsuo T; Izumi Y; Wakita S; Kume T; Takada-Takatori Y; Sawada H; Akaike A
    Eur J Pharmacol; 2010 Aug; 640(1-3):68-74. PubMed ID: 20460122
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Delusional Parasitosis: Diagnosis and Treatment.
    Mumcuoglu KY; Leibovici V; Reuveni I; Bonne O
    Isr Med Assoc J; 2018 Jul; 20(7):456-460. PubMed ID: 30109800
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antipsychotic medication and seizures: a review.
    Hedges D; Jeppson K; Whitehead P
    Drugs Today (Barc); 2003 Jul; 39(7):551-7. PubMed ID: 12973403
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Delusional parasitosis over dermatological morbidity: diagnostic and therapeutic challenges.
    Suganthan JS; Rajkumar AP; Jagannath C; Pulimood SA; Jacob KS
    Trop Doct; 2009 Jan; 39(1):49-50. PubMed ID: 19211429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.